KSTI 2026 Promotes Investment Certainty for Pharmaceutical Downstreaming
Surabaya — Investment certainty is a key factor in accelerating the downstreaming and commercialisation of innovations in pharmaceuticals and medical devices. This was stated by Rakhmat Yulianto, Director of Promotion Development at the Ministry of Investment and Downstreaming/Investment Coordinating Board (Kemeninveshil/BKPM), during the Integrated Innovation Services session at the 2026 Science, Technology and Industry Convention (KSTI) at Grha Sepuluh Nopember, Sepuluh Nopember Institute of Technology (ITS), Surabaya, on Thursday (12 November).
Rakhmat explained that innovation in pharmaceuticals and medical devices requires a conducive investment climate so that research from universities and research institutions can be widely applied and generate economic value. He said the government and universities need to focus on strengthening investment to speed up the downstreaming of healthcare innovation in Indonesia.
“Both the government and universities need to emphasise the importance of strengthening investment to accelerate the downstreaming and commercialisation of healthcare innovation in Indonesia,” Rakhmat said.
He also said Indonesia’s pharmaceutical industry has significant market potential. National companies currently account for around 82 per cent of the domestic pharmaceutical market.
“This presents an opportunity to strengthen the domestic pharmaceutical industry, particularly by increasing production capacity and developing innovative products,” he said.
To support the industry’s development, the government is reforming policies to provide businesses with greater certainty. These measures include risk-based business licensing and the integration of licensing services across ministries and agencies through the Online Single Submission (OSS) system. The reforms have also been reinforced by Government Regulation No. 28 of 2025, which sets timeframes for licensing services and simplifies procedures. “These reforms are a concrete government measure to make business licensing easier, a process that the public, particularly business operators, have often complained about,” Rakhmat said.
In addition to simplifying licensing, the government offers incentives to encourage investment and innovation, including a super tax deduction that allows a reduction in gross income of up to 300 per cent of research and development costs. It also offers an investment allowance, allowing a reduction in net income of up to 60 per cent of the total investment in fixed assets. Rakhmat added that Kemeninveshil/BKPM supports innovators by helping them prepare investment and licensing plans, identify suitable incentives, and meet prospective industrial partners and investors.
“Support is also provided for preparing investment and licensing plans and identifying incentives suited to business development needs. In this case, Kemeninveshil connects innovators with prospective industrial partners and investors,” he said.
Rakhmat stressed that innovation requires collaboration among various parties through a pentahelix approach. The government provides policies and regulations, while academics and researchers generate innovation and develop human resources. Businesses, meanwhile, develop and produce innovations so they can be used more widely. The media, the public and non-governmental organisations (NGOs) also contribute by disseminating information and providing oversight.
The collaboration is expected to accelerate the use of healthcare research and increase the capacity of Indonesia’s pharmaceutical industry. These efforts are aligned with Sustainable Development Goal 3, on good health and well-being, and Goal 9, on industry, innovation and infrastructure.
Source: jawawa.id (https://jawawa.id/newsitem/ksti-2026-promotes-investment-certainty-for-pharmaceutical-downstreaming-1794477029)
Originally published by kemdiktisaintek.go.id (https://kemdiktisaintek.go.id/news/article/ksti-2026-dorong-kepastian-investasi-untuk-hilirisasi-farmasi), translated from Indonesian